Tecnovax denounced Biogenesis and CDV for ‘cartelization and higher place’ and is attempting to import the product from Brazil.
(NAP) On the firm Tecnovax offered a criticism earlier than the Nationwide Fee for the Safety of Competitors for alleged cartels and abuse of workplace dominate the laboratories Bagó Biogenesis and QOLthe 2 corporations that manufacture and promote the foot and mouth illness vaccine.
In its presentation, Tecnovax contends that the presumption of “prejudicial conduct, a unilateral and abusive change within the value of the tetravalent foot-and-mouth vaccine, discrimination towards the worth supplied, the linked sale and the refusal to promote. to the particular state of affairs of anti-competitive abuse of oligopolistic energy, as the one producers and suppliers of this product within the nation. “
“All these behaviors violate the Regulation on the Safety of Competitors and hurt not solely competitors however particularly producers and customers, thus harming the financial curiosity usually, and it’s that’s the reason it’s requested that the corresponding sanction be utilized if that occurs. they’re confirmed,” the present maintains.
The battle began months in the past after Tecnovax, protected by the Authorities’s deregulation plan, denied that Biogenesis Bagó and CDV have been promoting the vaccine at a lot greater costs in comparison with international locations close by.
“Vaccine costs in Argentina in February 2024 have been $1,430 per dose on the laboratory middle value, which is equal to $1.7 on the official trade fee at the moment, whereas in different international locations within the area it was between 0.35 and 0.75 {dollars}, that’s, 2 to 4 occasions cheaper,” the Argentine firm reveals.
Tecnovax doesn’t have a neighborhood manufacturing plant for the foot and mouth illness inoculum and it had introduced that it was going to import round 15 million doses from Brazil at half the worth of its rivals. being produced in Argentina. For imports, it signed a long-term provide settlement with the Brazilian laboratory Ourofino, for its bivalent vaccine Ourovac Aftosa. (Final yr Brazil introduced that it was freed from the illness and so they stopped vaccination).
Biogenesis and CDV defend the tetravalent nature of their vaccines. Within the dispute that was revealed this summer season, the Minister of Deregulation and Transformation of the State, Federico Sturzenegger, joined the battle, giving extra visibility to the dispute. And he put a quantity on it: about US$2,000 million.
“The dearth of competitors was based mostly on the duty to make use of unique strains solely to Argentina (A2001) till 2024, when Senasa launched that requirement beginning in 2025 and on too strict regulation. That’s the reason till now the present authorized regulation has not allowed the entry of latest vaccines, with tens of millions of doses accessible at aggressive costs that can’t enter Argentina due to the regulatory framework,” Tecnovax stated in its presentation.
On the similar time, Biogenesis Bagó and CDV deny Tecnovax’s accusations and level out that even the costs set by the plaintiff firm aren’t those truly paid by the producer, along with the truth that each corporations have been in a position to settle for Senasa’s new provisions with none form of inconvenience. The reality is that Biogenesis says that they haven’t been the one bidders for this million-dollar market and that it contains funding from the ranchers. (Agricultural Information)
Put up Views: 39
2024-07-15 18:04:58
#chapter #controversy #laboratories #foot #mouth #vaccines #AgroPecuarias #Information
